Scienture Holdings, Inc. 8-K

What Happened
Scienture Holdings, Inc. (SCNX) filed an 8-K reporting that Chief Financial Officer Eric Sherb resigned effective May 26, 2026, citing personal reasons and stating the departure was not due to any dispute with the company. The company appointed Dr. Narasimhan Mani (age 51) as Interim Chief Financial Officer effective the same date. Dr. Mani has served as a director and as Co‑Chief Executive Officer and President of Scienture since May 2025 and will continue under his existing employment agreement (as amended and previously disclosed).

Key Details

• Eric Sherb resigned as CFO effective May 26, 2026; resignation stated to be for personal reasons and not due to any disagreement with management or the board.
• Dr. Narasimhan Mani appointed Interim CFO effective May 26, 2026; he has been a director and Co‑CEO/President since May 2025.
• Dr. Mani (B.Pharm; M.S. Analytical Chemistry; Ph.D. Pharmaceutics; MBA, Columbia) has 25+ years in pharma and has held finance and strategy roles at Kesin Pharma, Xiromed, Amneal, Johnson & Johnson, Forest Labs, and Par Pharmaceuticals.
• Company disclosed there are no special arrangements or family relationships related to Dr. Mani’s selection and no material transaction interests requiring Item 404 disclosure.

Why It Matters
This is an Item 5.02 executive change affecting the company’s finance leadership. For investors, the appointment of an experienced internal executive with finance and industry experience may support continuity in financial planning, reporting, and operations while the company searches for a permanent CFO. The filing also notes the resignation was not due to a dispute, which reduces immediate governance concerns. Investors should watch for any future updates on a permanent CFO search and any potential impacts on financial disclosure or guidance.